These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 37489368)

  • 41. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.
    Kholodenko RV; Kalinovsky DV; Doronin II; Ponomarev ED; Kholodenko IV
    Curr Med Chem; 2019; 26(3):396-426. PubMed ID: 28820071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monoclonal antibodies based on hybridoma technology.
    Yagami H; Kato H; Tsumoto K; Tomita M
    Pharm Pat Anal; 2013 Mar; 2(2):249-63. PubMed ID: 24237029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.
    Effer B; Perez I; Ulloa D; Mayer C; Muñoz F; Bustos D; Rojas C; Manterola C; Vergara-Gómez L; Dappolonnio C; Weber H; Leal P
    Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand.
    Zambrano N; Froechlich G; Lazarevic D; Passariello M; Nicosia A; De Lorenzo C; Morelli MJ; Sasso E
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The expanding role of synthetic nucleic acids for diagnosis and treatment.
    Arinuma Y
    Curr Opin Neurol; 2022 Jun; 35(3):423-426. PubMed ID: 35283462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoclonal antibodies as innovative anti-infective agents.
    Reichert JM
    Discov Med; 2005 Dec; 5(30):544-7. PubMed ID: 20704838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update.
    Mukhopadhyay D; Ahmed A; Sano C; Awad N; Al Sawaftah N; Husseini GA
    Curr Protein Pept Sci; 2021; 22(6):493-504. PubMed ID: 33583369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomaterials-Based Delivery of Therapeutic Antibodies for Cancer Therapy.
    Ye QN; Wang Y; Shen S; Xu CF; Wang J
    Adv Healthc Mater; 2021 Jun; 10(11):e2002139. PubMed ID: 33870637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
    Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
    J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The development of methods for obtaining monoclonal antibody-producing cells].
    Skowicki M; Lipiński T
    Postepy Hig Med Dosw (Online); 2016 Apr; 70():367-79. PubMed ID: 27117113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.
    Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB
    Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new era for monoclonal antibodies with applications in neurology (Review).
    Sirbu CA; Ghinescu MC; Axelerad AD; Sirbu AM; Ionita-Radu F
    Exp Ther Med; 2021 Jan; 21(1):86. PubMed ID: 33363597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Holdase/Foldase Mimetic Nanochaperone Improves Antibody-Based Cancer Immunotherapy.
    Zhang Y; Fu H; Chen J; Xu L; An Y; Ma R; Zhu C; Liu Y; Ma F; Shi L
    Small Methods; 2023 May; 7(5):e2201051. PubMed ID: 36228110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies.
    Alhazmi HA; Albratty M
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The state-of-play and future of antibody therapeutics.
    Elgundi Z; Reslan M; Cruz E; Sifniotis V; Kayser V
    Adv Drug Deliv Rev; 2017 Dec; 122():2-19. PubMed ID: 27916504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glycosylation-dependent antitumor therapeutic monoclonal antibodies.
    Zhang Y; Fan C; Zhang L; Ma X
    Prog Mol Biol Transl Sci; 2019; 163():471-485. PubMed ID: 31030759
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.
    Davidson E; Bryan C; Fong RH; Barnes T; Pfaff JM; Mabila M; Rucker JB; Doranz BJ
    J Virol; 2015 Nov; 89(21):10982-92. PubMed ID: 26311869
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Controlled-release and local delivery of therapeutic antibodies.
    Grainger DW
    Expert Opin Biol Ther; 2004 Jul; 4(7):1029-44. PubMed ID: 15268671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.